Search - tctmd.com

Displaying 21 - 40 of 426

Sort: Relevancy | Date

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Caitlin E. Cox

April 14, 2025

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Genetic Risk Score for Endothelial Cell Dysfunction Identifies Patients at Risk

News Daily News

Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care

Michael O'Riordan

February 27, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

News Conference News AHA 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Caitlin E. Cox

November 21, 2024

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

News Daily News

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Michael O'Riordan

November 13, 2024

News Opinion Off Script

Talking Politics With Patients? In This Election, I Can’t Hold My Tongue

Jonathan S. Reiner, MD

October 27, 2024

Presentation TCT 2024

Changes in Plaque Volume and Plaque Composition After 12 Weeks of Extensive LDL-C Reduction With PCSK9 Inhibitors in ACS Patients With Multivessel Disease

Presenter: Jonathan Los

October 27, 2024

News Daily News

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Michael O'Riordan

October 14, 2024

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

News Daily News

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Michael O'Riordan

July 29, 2024

News Conference News ACC 2024

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Yael L. Maxwell

July 03, 2024

Advertisement

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Talking Politics With Patients? In This Election, I Can’t Hold My Tongue

Changes in Plaque Volume and Plaque Composition After 12 Weeks of Extensive LDL-C Reduction With PCSK9 Inhibitors in ACS Patients With Multivessel Disease

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content